Drugs of Interest for T-ALL
| Target . | Type of drug . | Agents . |
|---|---|---|
| Notch49 | γ-secretase inhibitors | RO4929097, BMS906024, PF03084014, LY3039478, MK0752 |
| Monoclonal antibodies (anti-Notch1, anti-Notch2, anti-DLL4) | OMP52M51, OMP59R5, REGN421 | |
| Soluble notch proteins | Preclinical only | |
| Mastermind inhibiting peptides | Preclinical only | |
| PI3K/Akt/mTOR51 | PI3K inhibitors | BYL719, idelasib, GSK2636771, BKM120, BAY80-6946, IPI145, TGR1202, AMG319, SAR260301 |
| Rapalogs (mTOR inhibitors) | Sirolimus, everolimus, temsirolimus, ridaforolimus | |
| PI3K/mTOR inhibitors | BEZ235, GDC0980, VS5584, SAR245409 | |
| Akt inhibitors | MK2206, GSK2110183 | |
| mTORC1/2 inhibitors | OSI027, DS-3078a, CC223 | |
| Jak/Stat61 | Jak1/2 | Ruxolitinib, momelotinib |
| Jak 2 inhibitors | Fedratinib, pacritinib, BB594 | |
| Stat inhibitors | C1889, pimozide, S31201, STA21 | |
| MAPK62 | MEK inhibitors | Trametinib, pimsertib, cobimetinib, selumetinib |
| Farnesyl transferase inhibitors | Tipifarnib | |
| Cell cycle Machinery63 | CDK4/6 inhibitors | Palbociclib, ribociclib, abemaciclib |
| Pan-CDK inhibitors | Flavopiridol, dinaciclib, AT7519 | |
| Proteasome57 | Proteasome inhibitors | Bortezomib, carfilzomib, ixazomib |
| Deubiquinating enzymes | Preclinical only | |
| Neddylation inhibitors | MLN49243 | |
| E3 ubiquitin ligase inhibitors | Preclinical only | |
| Epigenetic58 | HDAC inhibitors | Vorinostat, romidepsin, SAHA |
| DNA methyltransferase inhibitors | 5-azacitidine, decitabine | |
| IDH1/2 inhibitors | AGI6780, AGI5198, AG221 | |
| BRD4 inhibitors | JQ1, OTX015 | |
| DOT1L inhibitors | EPZ004777, EPZ5676 | |
| Immunotherapy59 | Monoclonal antibodies | Daratumomab, basiliximab, alemtuzumab |
| BiTEs, CARs | Preclinical only |
| Target . | Type of drug . | Agents . |
|---|---|---|
| Notch49 | γ-secretase inhibitors | RO4929097, BMS906024, PF03084014, LY3039478, MK0752 |
| Monoclonal antibodies (anti-Notch1, anti-Notch2, anti-DLL4) | OMP52M51, OMP59R5, REGN421 | |
| Soluble notch proteins | Preclinical only | |
| Mastermind inhibiting peptides | Preclinical only | |
| PI3K/Akt/mTOR51 | PI3K inhibitors | BYL719, idelasib, GSK2636771, BKM120, BAY80-6946, IPI145, TGR1202, AMG319, SAR260301 |
| Rapalogs (mTOR inhibitors) | Sirolimus, everolimus, temsirolimus, ridaforolimus | |
| PI3K/mTOR inhibitors | BEZ235, GDC0980, VS5584, SAR245409 | |
| Akt inhibitors | MK2206, GSK2110183 | |
| mTORC1/2 inhibitors | OSI027, DS-3078a, CC223 | |
| Jak/Stat61 | Jak1/2 | Ruxolitinib, momelotinib |
| Jak 2 inhibitors | Fedratinib, pacritinib, BB594 | |
| Stat inhibitors | C1889, pimozide, S31201, STA21 | |
| MAPK62 | MEK inhibitors | Trametinib, pimsertib, cobimetinib, selumetinib |
| Farnesyl transferase inhibitors | Tipifarnib | |
| Cell cycle Machinery63 | CDK4/6 inhibitors | Palbociclib, ribociclib, abemaciclib |
| Pan-CDK inhibitors | Flavopiridol, dinaciclib, AT7519 | |
| Proteasome57 | Proteasome inhibitors | Bortezomib, carfilzomib, ixazomib |
| Deubiquinating enzymes | Preclinical only | |
| Neddylation inhibitors | MLN49243 | |
| E3 ubiquitin ligase inhibitors | Preclinical only | |
| Epigenetic58 | HDAC inhibitors | Vorinostat, romidepsin, SAHA |
| DNA methyltransferase inhibitors | 5-azacitidine, decitabine | |
| IDH1/2 inhibitors | AGI6780, AGI5198, AG221 | |
| BRD4 inhibitors | JQ1, OTX015 | |
| DOT1L inhibitors | EPZ004777, EPZ5676 | |
| Immunotherapy59 | Monoclonal antibodies | Daratumomab, basiliximab, alemtuzumab |
| BiTEs, CARs | Preclinical only |